簡(jiǎn)要描述:艾滋病病毒EP1抗體免 疫 原;KLH conjugated synthetic peptide derived from human HIVEP1: 2001-2100/2718
產(chǎn)品分類(lèi)
Product Category相關(guān)文章
Related Articles詳細(xì)介紹
艾滋病病毒EP1抗體
產(chǎn)品名稱(chēng) | 英文名稱(chēng) | 貨號(hào) |
艾滋病病毒EP1抗體 | HIVEP1 | GOY-01K5313 |
商品屬性:
英文名稱(chēng): HIVEP1
中文名:艾滋病病毒EP1抗體
別 名;Cirhin
interaction protein; CIRIP; CRYBP1; GAAP; Gate keeper of apoptosis-activating
protein; HIV EP1; HIV-EP1; HIVEP 1; Hivep1; Human immunodeficiency virus type I
enhancer binding protein 1; Human immunodeficiency virus type I
enhancer-binding protein 1; Major histocompatibility complex binding protein 1;
Major histocompatibility complex-binding protein 1; MBP 1; MBP-1; Positive
regulatory domain II binding factor 1; Positive regulatory domain II-binding
factor 1; PRDII BF1; PRDII-BF1; Schnurri 1; ZAS1; ZEP1_HUMAN; Zinc finger
protein 40; ZNF40; ZNF40A.
研究領(lǐng)域;細(xì)胞生物 轉(zhuǎn)錄調(diào)節(jié)因子 結(jié)合蛋白 表觀遺傳學(xué)
抗體來(lái)源;Rabbit
克隆類(lèi)型;Polyclonal
交叉反應(yīng);(predicted:
Human, Mouse, Rat, Dog, Pig, Cow, Horse, Sheep, )
產(chǎn)品應(yīng)用;ELISA=1:5000-10000
IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100-500 IF=1:100-500 (石蠟切片需做抗原修復(fù))
not yet tested in
other applications.
optimal
dilutions/concentrations should be determined by the end user.
理論分子量;297kDa
細(xì)胞定位;細(xì)胞核 細(xì)胞漿
性 狀;Liquid
濃 度;1mg/ml
免 疫 原;KLH
conjugated synthetic peptide derived from human HIVEP1: 2001-2100/2718
亞 型;IgG
純化方法;affinity
purified by Protein A
緩 沖 液;0.01M
TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
注意事項(xiàng);This
product as supplied is intended for research use only, not for use in human,
therapeutic or diagnostic applications.
產(chǎn)品介紹:
This protein specifically binds to the DNA
sequence 5'-GGGACTTTCC-3' which is found in the enhancer elements of numerous
viral promoters such as those of SV40, CMV, or HIV-1. In addition, related
sequences are found in the enhancer elements of a number of cellular
promoters, including those of the class I MHC, interleukin-2 receptor, and
interferon-beta genes. It may act in T-cell activation. Involved in
activating HIV-1 gene expression. Isoform 2 and isoform 3 also bind to the
IPCS (IRF1 and p53 common sequence) DNA sequence in the promoter region of
interferon regulatory factor 1 and p53 genes and are involved in
transcription regulation of these genes. Isoform 2 does not activate HIV-1
gene expression. Isoform 2 and isoform 3 may be involved in apoptosis. |
多克隆抗體制備:
我公司合成抗原,保證陽(yáng)性血清和抗體ELISA效價(jià)達(dá)到1:32000,由蛋白抗原制備的多抗,保證WB檢測(cè)結(jié)果是陽(yáng)性。技術(shù)服務(wù)實(shí)行分步報(bào)價(jià),按節(jié)點(diǎn)收費(fèi),為客戶(hù)節(jié)約成本。
鼠單克隆抗體制備:
客戶(hù)可根據(jù)項(xiàng)目實(shí)際需求情況靈活選擇進(jìn)行,我公司將為您的項(xiàng)目提供專(zhuān)業(yè)的建議。在制備過(guò)程中,與客戶(hù)互動(dòng)驗(yàn)證,確保最終制備的抗體ELISA陽(yáng)性血清檢測(cè)達(dá)到合同要求的同時(shí),也能滿(mǎn)足客戶(hù)抗體最終應(yīng)用驗(yàn)證需求。技術(shù)服務(wù)實(shí)行分步報(bào)價(jià),按節(jié)點(diǎn)收費(fèi),為客戶(hù)節(jié)約成本。
重組抗體表達(dá)服務(wù):
重組抗體技術(shù)使制備人源化抗體和人源抗體成為可能,而這是其他常規(guī)的多克隆或單克隆抗體制備方法無(wú)法做到的。我公司已搭建好的抗體測(cè)序、重組抗體表達(dá)等先進(jìn)平臺(tái),能為客戶(hù)提供各種類(lèi)型的重組抗體表達(dá)服務(wù),包含鼠源單克隆抗體構(gòu)建及表達(dá)、更換恒定區(qū)亞型的嵌合抗體表達(dá),抗體人源化改造及表達(dá)等服務(wù)。
單項(xiàng)免疫學(xué)及檢測(cè)服務(wù):
我公司也為客戶(hù)提供單項(xiàng)免疫學(xué)和檢測(cè)服務(wù),如動(dòng)物免疫、動(dòng)物飼養(yǎng)、抗體修飾服務(wù)(如FITC,HRP等的標(biāo)記)、以及ELISA,WB,IHC,DB等檢測(cè)服務(wù)。
抗體定制服務(wù):
已注冊(cè)商標(biāo),主要用于抗體藥物發(fā)現(xiàn)和開(kāi)發(fā),是我公司針對(duì)有特定應(yīng)用要求和各種模型測(cè)試的客戶(hù)量身定制的專(zhuān)業(yè)服務(wù),主要面向工業(yè)客戶(hù)。
產(chǎn)品咨詢(xún)
歡迎您關(guān)注我們的微信了解更多信息
電話(huà)
微信掃一掃